This unique publication explores diverse themes relating to thrombosis and embolism, from basic research at cell and molecular level to the actual care, prevention, and treatment of diverse categories of patients suffering from such diseases. Chapters cover a variety of topics including thrombosis and embolism in surgical patients, cancer patients, pregnant women and children and adolescents, as well as treatment of the conditions by traditional anticoagulants, novel oral anticoagulants, thrombolytic therapy, endovascular treatment and embolectomy. Readers may explore cutting edge research, recommendations from major societies, contemporary guidelines, areas of controversy and directions for ongoing and future research. The book features comprehensive information ranging from molecular mechanisms of diseases to the clinical features, diagnosis, and therapeutic regimens for treating a variety of clinical conditions. It has a broad appeal to scientists and research students as well as busy clinicians engaged in patient care, who will all find something important and useful amongst these carefully selected chapters.

ASCP requirement. "To pass the ASCP and become a licensed medical lab tech, this text is the ultimate blood bank source for the required classes." - Amazon Reviewer "Great resource for anyone in a Medical Technology or Medical Laboratory Science Program! I would highly recommend this book!" - Mary L., Amazon Reviewer "Amazing legendary book in the field. Helpful for practicing Transfusion Medicine and Hematology." - Zubair S., Amazon Reviewer Join the generations of students who have embarked on successful careers with a firm foundation in the theory and practice of blood banking and transfusion practices. Denise Harmening's classic text teaches you not only how to perform must-know tests and tasks, but to understand the scientific principles behind them. You'll begin with a review of the basic concepts of red blood cell and platelet preservation, genetics, immunology, and molecular biology. Then you'll move to the hows and whys of clinical practice. And, you'll be prepared for new advances in the field.

This book discusses the aspects of haploidentical transplants and will shed light on the debates and questions on this burgeoning field and timely topic. Donor selection, graft failure, minimal CD34+ cell requirement, and conditioning regimens used for haploidentical transplants will be written by expert authors dealing with this type of transplants. Approximately one third of the books' chapters cover logic and basic aspects; the remaining two thirds of the book discuss clinical aspects, outcomes, and future perspectives, thus providing a comphrensive discussion of the topic. Haploidentical transplantation is extremely timely, rapidly-changing area and increasing its use will decrease the need for time-consuming, expensive, unrelated donor search. Moreover, Haploidentical Stem Cell Transplantation brings a set of clear answers to questions of feasibility, advantages over unrelated transplants, cost effectivity and outcome..

This book is an up-to-date reference on all aspects of anticoagulation and hemostasis in neurosurgery. After an opening section on basic principles and drug classes in current use, detailed consideration is given to coagulation issues relevant to all patients, not just neurosurgical ones. The coverage includes, for example, deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation. A variety of important issues specific to neurosurgical practice are then addressed, and a summary of current guidelines and best practices is provided. By bringing together the latest knowledge from across the discipline, this book will serve as a sound basis for informed decision making in surgical practice. It will be of daily value for neurosurgeons and trainees worldwide and will also be of interest to emergency room physicians, surgeons in general, critical care physicians, neurologists, and hospital medicine specialists.

, For the most part we. the haemophiliacs present at this Congress. have come from the great metropolitan centres with their advanced medical and social programmes for sufferers of haemophilia. We. the fortunate from the haemophilia oasis. have much to learn from each other. This is important. but even more important is the urgency to convey your knowledge. your skills. your experience and your dedication to the haemophiliacs in the desert: 'We can only begin to understand the condition. the life of a sufferer. by comparing him to a soldier in the trenches of World War I. In the trenches the soldier seldom forgets that the next moment may bring death or crippling. The haemophiliac is literally in the trenches. The soldier may be spared injury. but pain awaits the haemophiliac. Fear. moreover, is paramount to the pain. As in the trenches. the anxiety can be more oppressive than the wound. Waiting to go over the top imposes a greater strain than the actual charge. For the soldiers that survived World War I in the trenches. 4 years seemed eternity; the haemophiliac never leaves the battlefield: Opening Address, Frank Schnabel. World Federation of Hemophilia. Copenhagen. June 25th. 1963. War can come to an oasis, peace can come to the trenches. With this book, Dr Peter Jones has joined the international struggle. Carefully, concisely and cogently. the text offers a grand strategy. With allies like Dr Jones we will, one day, achieve victory. Frank Schnabel, Chairman.

This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenstroem's macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.

This unique book focuses on the non-myeloma plasma cell dyscrasias. A key resource for this group of diseases, the book features the latest in emerging knowledge and therapeutic developments, including novel therapies. Each disease-specific chapter discusses biology, disease course, and appropriate therapeutic interventions, covering plasma cell leukemia, plasmacytoma, POEMS Syndrome and Castleman's Disease, Waldenstroem macroglobulinemia, immunoglobin deposition disease, and cryoglobulinemic syndromes, among others. The only book dedicated to this intriguing family of diseases, Biology and Management of Unusual Plasma Cell Dyscrasias will be a long-lasting reference for clinicians and scientists alike.

Childhood acute leukemias are one of the main causes of death in children aged 1 to 14 years in some countries; and unfortunately, we have been unable to prevent it. Certainly, a good parcel of it is due to the poor understanding about its etiology. This book aims to describe the most important theories and hypothesis regarding childhood acute leukemia. Written by the most outstanding researchers in the field, this book intends to contribute to a greater understanding of the etiology of this disease. It goes beyond the simple and common analysis of risk factors, which hardly allows us to draw definite conclusions. By addressing the etiology of the disease, discussing from molecular biology until epidemiology and clinical manifestations, this book will guide present and future approaches, contributing for a better clinical management of leukemia in children. The knowledge regarding etiology is a crucial step for a better evaluation, prevention and treatment of a disease. Thus, this book finally intends to provide such knowledge, allowing physicians and practitioners to a better manage of childhood acute leukemias.

Relapse of leukemia following successful remission-induction therapy remains a major obstacle in the treatment of patients with acute leukemia. Leukemia recurs most frequently in patients with acute myeloblastic leukemia (AML) and high risk acute lymphoblastic leukemia (ALL) following chemotherapy and less often in patients with low risk ALL and particularly in patient groups> submitted to allogeneic marrow transplantation. ' It is likely that the great majority of these recurrences originate from residual leukemic cells that survive initial remission-induction chemotherapy. Today, several research groups throughout the world place emphasis on studies concerned with the detection and treatment of 'minimal residual disease' (MRD). These investigations are conducted with the common objective to tackle the remaining cells. 'Minimal Residual Disease in Acute Leukemia: 1986' summarizes the fast advancements in this area. Several disciplines are concerned with the analysis of leukemic cells. The perspectives of cytogenetic and molecular genetic approaches for applica tion in the detection of MRD are reviewed. In this respect, modern cyto genetics provide highly specific tumor markers. The resolution of cyto genetic methods can be particularly improved when combined with other techniques which select relevant subpopulations of cells. Characterization of oncogenes and gene rearrangements, including those of immunoglobulin and T-cell receptor genes, and the measurement of gene products, have been established. Techniques based on these approaches offer interesting tools for the detection of MRD. New possibilities of employing monoclonal anti bodies are also presented.

This book illustrates applications of mathematics to various processes (physiological or artificial) involving flowing blood, including hemorheology, microcirculation, coagulation, kidney filtration and dialysis, offering a historical overview of each topic. Mathematical models are used to simulate processes normally occurring in flowing blood and to predict the effects of dysfunctions (e.g. bleeding disorders, renal failure), as well as the effects of therapies with an eye to improving treatments. Most of the models have a completely new approach that makes patient-specific simulations possible. The book is mainly intended for mathematicians interested in medical applications, but it is also useful for clinicians such as hematologists, nephrologists, cardio-surgeons, and bioengineers. Some parts require no specific knowledge of mathematics. The book is a valuable addition to mathematics, medical, biology, and bioengineering libraries.

Remarkable developments in the field of transplantation have created opportunities to address the formidable challenges of transplantation across histocompatibility barriers, stem cell expansion, and prevention of complications and generation of graft-vs-tumor activity to eradicate residual disease. Stem Cell Transplantation for Hematologic and Other Disorders, Second Edition provides a glimpse into potential future applications of bone marrow derived stem cells in the field of cardiac repair. The updated chapters introduce the biologic underpinnings of hematopoietic cell transplantation, basic stem cell biology, immunobiology, and histocompatibility, with emphasis on indications and results of transplantation for specific diseases. Written by experts in the field, Stem Cell Transplantation for Hematologic Disorders, Second Edition provides seasoned professionals with a complete understanding of the current state of transplantation biology as well as a clear vision into the future.

Anemia, a frequent complication of cancer and its treatments, produces unwanted symptoms and significantly impairs metabolic and physiologic functions, as well as patients' activity, quality of life and even life expectancy. In its new Second Edition, this book presents current knowledge on anemia in cancer and its treatment with Recombinant Human Erythropoietin (rhEPO). Expanded, updated and newly added chapters describe scientific and clinical aspects of anemia, and give diagnostic and therapeutic recommendations on use of rhEPO. This is an essential source of information for radiotherapists, medical oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion and laboratory medicine, and pharmacologists.

Introduction The understanding of the genetic, epigenetic, immuno- well as for practicing hematologists or oncologists. logical and biological causes of myeloproliferative dis- Each chapter follows a similar architecture and leads orders has substantially improved in the last few years. through epidemiology, genetic and molecular causes, Together with refined tools in pathology, the successful hematological and clinical findings, prognostic factors establishment of mouse models mimicking at least some and current treatment approaches of the diseases. of the myeloproliferative disorders, and murine models Effort has been made to point out the evolving field of novel drugs in this arena but simultaneously diff- allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to entiate between standard and experimental treatment ever increasing numbers of modified classification approaches. schemes. It is therefore important for the heamtologist Together with the co-editors and all the authors of or oncologist to keep up with this rapid change in classi- the various chapters I hope that the readers of the book fication language, the upcoming of new entities or differ- will enjoy reading and benefit from the information entiation between, or subclassification of, rare diseases provided.

The mature T and NK cell lymphomas are rare, comprising approximately 10% of all malignant lymphomas. The incidence of T-cell lymphoma is variable around the world, with a higher incidence compared to B-cell lymphomas in the Asian basin. While the overall incidence of B-cell lymphomas has begun to decline in the United States, the incidence of T-cell lymphomas continues to rise. Over the last decade, a number of novel agents have been developed which target T-cell lymphomas and studies have identified novel genes and pathways associated with lymphomagenesis in T-cells. This comprehensive volume examines the clinical and biological aspects of the T-cell lymphoproliferative disorders in adults and children. The book includes an overview of both the cutaneous and the systemic T-cell malignancies and addresses the classification of T-cell lymphomas, the clinical features of each subtype, and the relevant molecular and genetic studies. Clinical outcomes and treatment strategies are discussed with an emphasis on the development of novel biological and targeted therapies. An outstanding resource for hematologists and oncologists, this book gathers insights from experts in the field and provides the most up-to-date information on all of the T-cell lymphoma subgroups and current and emerging therapies.

While a pattern approach to diagnosis is taught and practiced with almost every other tissue or organ in the body, the lymph node remains a mystery to most residents starting out in pathology and those pathologists with limited experience in the area. A Pattern Approach to Lymph Node Diagnosis demonstrates that a systematic approach to lymph node examination can be achieved through recognition of morphological patterns produced by different disease processes. It presents a combination of knowledge-based assessment and pattern recognition for diagnosis covering the major primary neoplastic and non neoplastic diseases and metastatic tumors in lymph nodes. This volume demonstrates that lymph node compartments can be recognized histologically especially with the aid of immunohistological markers and how this knowledge can be employed effectively to localize and identify pathological changes in the different compartments in order to facilitate histological diagnosis. It also defines histological features that, because of their pathological occurrence in lymph nodes, are useful pointers to specific diagnoses or disease processes. The volume is organized in accordance with the primary pattern of presentation of each diagnostic entity. Differential diagnosis is discussed and each diagnostic entity is accompanied by color illustrations that highlight the diagnostic features. Immunohistochemistry, clinical aspects, relevant cytogenetics and molecular information of each entity is provided by authors who are experts in lymphoproliferative diseases. An algorithmic approach to diagnosis is adopted at the end of each section by listing a set of questions that help to consider diagnostic entities that can present with the morphological features observed. A Pattern Approach to Lymph Node Diagnosis will be of great utility to residents and fellows in pathology and general pathologists making first hand lymph node diagnoses as well as to hematologists and physicians who treat patients with lymphoprolifeative diseases.

Many diseases earlier considered to be incurable are now being treated with modern innovations involving fetal tissue transplants and stem cells derived from fetal tissues. Fetal tissues are the richest source of fetal stem cells as well as other varying states of differentiated cells and support or stromal cells. The activity of such stem cells is at their peak provided they are given the correct niche. Stem cells, as we know, are immortal cells with the capacity to regenerate into any kind of differentiated cell as per niche-guidance. As such, fetal tissues have the potential capacity to mend, regenerate and repair damaged cells or tissues in adults, when directly transplanted to the site of injury, or even when transplanted in some other site, because it may have a homing capacity to migrate to the site of the specific injured organ. This is a new area of translational research and needs to be highlighted because of its immense potential. This book will bring together the new work of prominent medical scientists and clinicians who are conducting pioneering research in human fetal tissue transplantation. This will include direct transplant of healthy fetal tissue into mature patients as well as in hosts with genetic diseases. Transplant techniques, donor-host interaction, cell and tissue storage, ethical and legal issues, are some of the many matters which the book will deal with.

The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors. This is the first book to focus exclusively on the adult ALL patient. It provides a complete overview of diagnosis, molecular pathogenesis, evaluation, and treatment for this important patient population.

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.

A real boon for medical practitioners from a number of disciplines, this is a practice-oriented manual of medical oncology and hematology for day-to-day use in caring for patients' hematologic and neoplastic diseases. It is founded on the longstanding experience of a large specialized university department accustomed to having to provide reliable advice in a broad range of circumstances. The authors have chosen not to give a comprehensive review of the various subjects but have instead focused on practical methods which have proven to be useful in their experience, with special emphasis on standardizing chemotherapy protocols.

The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders is now being translated into treatment approaches that target the epigenetic defects pharmacologically. This book first presents the latest evidence regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.

Currently, hemoglobin (Hb)-based oxygen carriers (HBOCs) are leading candidates as red blood cell substitutes. In addition, HBOCs are also potential oxygen therapeutics for treatment of patients with critical ischemic conditions due to atherosclerosis, diabetes and other conditions. This book will provide readers a comprehensive review of topics involved in the HBOC development. It focusses on current products and clinical applications as well as on emerging technologies and future prospects.

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

Blood science has become a cornerstone of multiple disciplines, including clinical chemistry, disease diagnosis, and therapeutic monitoring. Over the past decade, we have witnessed the advent of increasingly powerful proteomics technologies that allow greater fundamental insights into the blood proteome. These technological improvements have, in part, fuelled the quest for the discovery of novel blood-based biomarkers of disease. Serum/Plasma Proteomics: Methods and Protocols is a comprehensive resource of protocols for areas, pre-analytical through to analytical, of plasma and serum proteomics. Divided into five convenient sections, this detailed volume covers fractionation strategies for in-depth blood proteome analysis, defined procedures for blood collection, handling and storage, detailed protocols for performing both antibody-based and non-antibody based quantitative assays, proteome analysis of blood cell compartments, circulating nanomebraneous vesicles and blood-related fluids, and finally data management, statistical design, and bioinformatic challenges. This book, contributed to by leading experts in the field, provides a valuable foundation for the development and application of blood-based proteomics. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters contain introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easily accessible, Serum/Plasma Proteomics: Methods and Protocols, with its well-honed methodologies, seeks to serve both professionals and investigators new to the field in an effort to further our knowledge of this fundamental science.